Figure 1.
A–C, Selected ongoing randomized trials of novel antitumor therapies in neuroendocrine tumors. IFN—interferon; IV—intravenously; LAR—long-acting release; PFS—progression-free survival; PO—orally; RADIANT—An Open Label, Stratified, Single-Arm Phase II Study of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumor (NET) After Failure of Cytotoxic Chemotherapy; SC—subcutaneously.